Cargando...
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has al...
Gardado en:
| Publicado en: | J Immunol Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Hindawi
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5932485/ https://ncbi.nlm.nih.gov/pubmed/29850622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/2386187 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|